MYSM1 (Myb-like, SWIRM, and MPN domains-containing protein 1) is a histone 2A deubiquitinase that plays a critical role in epigenetic regulation, DNA damage repair, and immune system modulation. It functions by removing ubiquitin moieties from histone H2A at lysine 119 (H2AK119ub), a post-translational modification associated with transcriptional repression. MYSM1 is essential for hematopoietic stem cell maintenance, lymphocyte development, and inflammatory response regulation. Dysregulation of MYSM1 has been implicated in immune disorders, bone marrow failure syndromes, and certain cancers.
MYSM1 antibodies are immunological tools designed to detect and quantify MYSM1 protein expression in research applications. These antibodies are typically developed using immunogenic peptides or recombinant protein fragments of MYSM1. often raised in hosts like rabbits or mice. They are widely used in techniques such as Western blotting, immunoprecipitation, immunofluorescence, and chromatin immunoprecipitation (ChIP) to study MYSM1's localization, interactions, and functional roles. Validated MYSM1 antibodies help elucidate its involvement in chromatin remodeling, gene expression control, and cellular responses to DNA damage.
Research utilizing MYSM1 antibodies has revealed its dual role in both activating and repressing transcription, depending on cellular context. Its deficiency is linked to impaired B-cell differentiation and immune dysregulation. Commercially available MYSM1 antibodies are often characterized for specificity using knockout cell lines or tissues. These reagents are pivotal for advancing studies in immunology, cancer biology, and regenerative medicine, offering insights into MYSM1's therapeutic potential as a target for inflammatory diseases or malignancies.